SEC Form 4 filed by Gonsalves Rodney (Amendment)

$A
Biotechnology: Laboratory Analytical Instruments
Industrials
Get the next $A alert in real time by email
SEC FORM 4/A SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Gonsalves Rodney

(Last) (First) (Middle)
5301 STEVENS CREEK BLVD

(Street)
SANTA CLARA CA 95051

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
AGILENT TECHNOLOGIES, INC. [ A ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
V.P., Corporate Controller
3. Date of Earliest Transaction (Month/Day/Year)
09/28/2023
4. If Amendment, Date of Original Filed (Month/Day/Year)
09/29/2023
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 09/28/2023 P 0(1) D $0 24,218.9301 D
Common Stock 40.192 I Gonsalves Trust(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Amended to report incorrect information generated by Fidelity Investments of purchase of 2.59 shares.
2. Shares held by the Gonsalves Trust for which Rodney and Rochelle Gonsalves are the trustees.
/s/ P. Diana Chiu, attorney-in-fact for Mr. Gonsalves 10/20/2023
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $A alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$A

DatePrice TargetRatingAnalyst
2/10/2025$135.00 → $145.00Underweight → Equal Weight
Barclays
8/28/2024$157.00Overweight
Wells Fargo
7/10/2024$135.00 → $150.00Neutral → Buy
Citigroup
6/27/2024Outperform → Peer Perform
Wolfe Research
6/3/2024$135.00Hold
Jefferies
4/5/2024$145.00 → $163.00Hold → Buy
Stifel
12/13/2023$140.00Outperform
Wolfe Research
12/12/2023$130.00 → $133.00Buy → Neutral
BofA Securities
More analyst ratings

$A
Press Releases

Fastest customizable press release news feed in the world

See more
  • Smackover Lithium's South West Arkansas Project Receives Unanimous Vote of Approval to Establish the Phase I Brine Production Unit from the Arkansas Oil and Gas Commission

    LEWISVILLE, Ark., April 24, 2025 (GLOBE NEWSWIRE) -- Smackover Lithium, a Joint Venture ("JV") between Standard Lithium Ltd. ("Standard Lithium" or the "Company") (TSXV:SLI) (NYSE:A) and Equinor, is pleased to announce that the brine production unit, now formally named the Reynolds Unit, for Phase I of its South West Arkansas ("SWA") Project has been unanimously approved by the Arkansas Oil and Gas Commission ("AOGC") with no objections or opposition in a hearing that was open to all stakeholders from the community. "We thank the AOGC for their due diligence in reviewing our application and for their swift approval," said Standard Lithium's President and COO, Dr. Andy Robinson, who prov

    $A
    $SLI
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Major Chemicals
  • Agilent Showcases Solutions and Partnerships Transforming Cancer Research and Therapeutics at AACR 2025

    Agilent Technologies Inc. (NYSE:A) announced today its participation at the American Association for Cancer Research (AACR) Annual Meeting on April 25-30, 2025 in Chicago, Illinois. Innovative Agilent products and partnerships playing a crucial role in transforming cancer research, diagnostics, and therapeutics will be featured, including: Agilent Avida DNA Cancer Panels – Based on cutting-edge next-generation sequencing (NGS) target enrichment solutions that enable simultaneous DNA and methylation profiling from a single sample, the Avida product portfolio has expanded to include three new DNA panels*. Optimized based on the requirements of the European OncNGS Consortium, these catalog p

    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • Smackover Lithium's South West Arkansas Project Receives Special Designation as a Priority Transparency Critical Mineral Project From the Trump Administration

    LEWISVILLE, Ark., April 21, 2025 (GLOBE NEWSWIRE) -- Smackover Lithium, a Joint Venture ("JV") between Standard Lithium Ltd. ("Standard Lithium" or the "Company") (TSXV:SLI) (NYSE:A) and Equinor, is proud to announce that its South West Arkansas ("SWA") Project has been selected as one of the first critical mineral production projects to be advanced under Executive Order 14241, Immediate Measures to Increase American Mineral Production, issued on March 20, 2025, by President Trump. This prestigious designation, announced by the Federal Permitting Improvement Steering Council at the recommendation of the National Energy Dominance Council, underscores the project's strategic importance to na

    $A
    $SLI
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Major Chemicals

$A
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$A
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$A
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$A
SEC Filings

See more

$A
Leadership Updates

Live Leadership Updates

See more
  • Agilent Showcases Solutions and Partnerships Transforming Cancer Research and Therapeutics at AACR 2025

    Agilent Technologies Inc. (NYSE:A) announced today its participation at the American Association for Cancer Research (AACR) Annual Meeting on April 25-30, 2025 in Chicago, Illinois. Innovative Agilent products and partnerships playing a crucial role in transforming cancer research, diagnostics, and therapeutics will be featured, including: Agilent Avida DNA Cancer Panels – Based on cutting-edge next-generation sequencing (NGS) target enrichment solutions that enable simultaneous DNA and methylation profiling from a single sample, the Avida product portfolio has expanded to include three new DNA panels*. Optimized based on the requirements of the European OncNGS Consortium, these catalog p

    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • Agilent to Acquire North American CDMO BIOVECTRA

    Expands Agilent's end-to-end biopharma solutions that accelerate drug discovery, development, and manufacturing Agilent Technologies Inc. (NYSE:A) today announced it has signed a definitive agreement to acquire BIOVECTRA, a leading specialized contract development and manufacturing organization, for $925 million. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240722078870/en/A BIOVECTRA manufacturing facility (Photo: Business Wire) Based in Canada, BIOVECTRA produces biologics, highly potent active pharmaceutical ingredients, and other molecules for targeted therapeutics. The acquisition builds on Agilent's CDMO specializati

    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • Politan Details Why a Truly Independent Board is Urgently Needed at Masimo in Order to Protect Shareholder Value and Realize the Company's Full Potential

    Sends Letter to Masimo Shareholders and Releases 160-Page Investor Presentation Urges Shareholders to Help Deliver Immediate Change by Voting for Both of Politan's Independent and Ideally Qualified Nominees Darlene Solomon and William Jellison on the WHITE Card Shareholders Can Visit www.AdvanceMasimo.com for Further Information Politan Capital Management (together with its affiliates, "Politan"), an 8.9% shareholder of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI), today sent a letter to the Company's shareholders outlining why a majority of truly independent directors are urgently needed in the Masimo boardroom. Politan also released a detailed investor presentation m

    $A
    $ANIK
    $AVNT
    $MASI
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Medical/Dental Instruments
    Health Care

$A
Financials

Live finance-specific insights

See more
  • Agilent to Announce Second-Quarter Fiscal Year 2025 Financial Results on May 28

    Agilent Technologies Inc. (NYSE:A) will release financial results for the second quarter of fiscal year 2025 after the stock market closes on Wednesday, May 28. In addition, the company will host a conference call to discuss the results at 1:30 p.m. PDT on the same day. To join the listen-only conference call webcast, click the link on the Events section of Agilent's investor relations website. A recording of the call also will be available on the website for 90 days. About Agilent Technologies Agilent Technologies Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Ag

    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • Agilent Reports First-Quarter Fiscal Year 2025 Financial Results

    Delivers solid Q1 results, confirms core growth and EPS for 2025 fiscal year First-quarter fiscal year 2025 Revenue of $1.68 billion for the first quarter ended Jan. 31, 2025, representing growth of 1.4% reported and up 1.2% on a core(1) basis compared with the first quarter of 2024. GAAP net income of $318 million; earnings per share (EPS) of $1.11, down 6% from the first quarter of 2024. Non-GAAP(2) net income of $377 million; EPS of $1.31, up 2% from the first quarter of 2024. Outlook for full 2025 fiscal year and Q2 Full-year revenue outlook is now in the range of $6.68 billion to $6.76 billion, representing a range of up 2.6% to 3.8% reported and 2.5% to 3.5% core(1).

    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • Agilent Announces Cash Dividend of 24.8 Cents per Share

    Agilent Technologies, Inc. (NYSE:A) today announced a quarterly dividend of 24.8 cents per share of common stock. The quarterly dividend will be paid on April 23, 2025, to all shareholders of record as of the close of business on April 1, 2025. The timing and amounts of future dividends are subject to determination and approval by Agilent's board of directors. About Agilent Technologies Agilent Technologies Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of solutions includes instruments, software, services, and expertise that provide trusted a

    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

$A
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more